A comparative study has suggested that Swiss pharma major Novartis’ (NOVN: GSK) Ultibro Breezhaler (indacaterol/glycopyrronium bromide) is consistently a more effective option than its rival from GlaxoSmithKline (LSE: GSK) for patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups.
The findings from the FLAME study, comparing the Ultibro Breezhaler with the UK pharma major’s Seretide (salmeterol/fluticasone propionate) across different patient sub-groups, are being presented at the European Respiratory Society (ERS) International Congress this week.
Once-daily Ultibro Breezhaler 110/50mcg demonstrated consistent reductions in all exacerbations regardless of age, smoking status, exacerbation history, disease severity, eosinophil levels and previous inhaled corticosteroid (ICS) use, versus twice-daily Seretide 50/500mcg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze